Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
TLDR
The theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed are examined.Abstract:
The first dominant SARS‐CoV‐2 Omicron variant BA.1 harbours 35 mutations in its Spike protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its discovery, BA.1 rapidly emerged to become the dominant variant worldwide and has since evolved into several variants. Omicron is of major public health concern owing to its high infectivity and antibody evasion. This review article examines the theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed. Added to the complexity of Omicron's evolution are the multiple reports of recombination events occurring between co‐circulating variants of Omicron with Delta and other variants such as XE. Current literature suggests that the combination of the novel mutations in Omicron has resulted in the variant having higher infectivity than the original Wuhan‐Hu‐1 and Delta variant. However, severity is believed to be less owing to the reduced syncytia formation and lower multiplication in the human lung tissue. Perhaps most challenging is that several studies indicate that the efficacy of the available vaccines have been reduced against Omicron variant (8–127 times reduction) as compared to the Wuhan‐Hu‐1 variant. The administration of booster vaccine, however, compensates with the reduction and improves the efficacy by 12–35 fold. Concerningly though, the broadly neutralising monoclonal antibodies, including those approved by FDA for therapeutic use against previous SARS‐CoV‐2 variants, are mostly ineffective against Omicron with the exception of Sotrovimab and recent reports suggest that the Omicron BA.2 is also resistant to Sotrovimab. Currently two new Omicron variants BA.4 and BA.5 are emerging and are reported to be more transmissible and resistant to immunity generated by previous variants including Omicron BA.1 and most monoclonal antibodies. As new variants of SARS‐CoV‐2 will likely continue to emerge it is important that the evolution, and biological consequences of new mutations, in existing variants be well understood.read more
Citations
More filters
Journal ArticleDOI
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
TL;DR: The theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed are examined.
Journal ArticleDOI
Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses
TL;DR: In this article , the authors examine challenges that have impeded development of effective mucosal respiratory vaccines, emphasizing that all of these viruses replicate extremely rapidly in the surface epithelium and are quickly transmitted to other hosts, within a narrow window of time before adaptive immune responses are fully marshaled.
Journal ArticleDOI
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
TL;DR: A review of the pathogenicity, mutations, treatments, and impact on the vaccine efficacy of the Delta and Omicron variants of SARS-CoV-2.2 can be found in this article .
Journal ArticleDOI
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani,Erika Leonardi,Attilio Cavezzi,Simona Ferrari,Oriana Iacono,Alice Limoli,Zoe Bouslenko,Daniele Natalini,Stefania Conti,Mauro Mantovani,Silvano Tramonte,Alberto Donzelli,Eugenio Serravalle +12 more
TL;DR: The vast majority of the individuals after suffering from COVID-19 develop a natural immunity both of cell-mediated and humoral type, which is effective over time and provides protection against both reinfection and serious illness.
Journal ArticleDOI
Insights for COVID-19 in 2023
Francisco Javier Martín Sánchez,Manuel Martínez-Sellés,Jose Maria Molero-García,S. Moreno Guillen,Fernando Rodríguez-Artalejo,Julian Ruiz-Galiana,Rafael Cantón,Pilar Ramos,Alejandra García-Botella,Alberto García-Lledó,Teresa Hernández-Sampelayo,Javier Gómez-Pavón,Juan González del Castillo,María Cruz Martín-Delgado,Emilio Bouza +14 more
TL;DR: A vaccine based on a recombinant protein that emulates the receptor binding domain of the Spike protein under development by the Spanish company Hipra, as well as vaccines for nasal or oral administration is presented in this article .
References
More filters
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Journal ArticleDOI
Nextstrain: real-time tracking of pathogen evolution.
James Hadfield,Colin Megill,Sidney M Bell,Sidney M Bell,John Huddleston,John Huddleston,Barney Potter,Charlton Callender,Pavel Sagulenko,Trevor Bedford,Richard A. Neher,Richard A. Neher,Richard A. Neher +12 more
TL;DR: Nextstrain consists of a database of viral genomes, a bioinformatics pipeline for phylodynamics analysis, and an interactive visualization platform that presents a real-time view into the evolution and spread of a range of viral pathogens of high public health importance.
Journal ArticleDOI
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Dora Pinto,Young-Jun Park,Martina Beltramello,Alexandra C. Walls,M. Alejandra Tortorici,M. Alejandra Tortorici,Siro Bianchi,Stefano Jaconi,Katja Culap,Fabrizia Zatta,Anna De Marco,Alessia Peter,Barbara Guarino,Roberto Spreafico,Elisabetta Cameroni,James Brett Case,Rita E. Chen,Colin Havenar-Daughton,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Antonio Lanzavecchia,Michael S. Diamond,Katja Fink,David Veesler,Davide Corti +25 more
TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Journal ArticleDOI
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
Carolyn Rydyznski Moderbacher,Sydney I. Ramirez,Sydney I. Ramirez,Jennifer M. Dan,Jennifer M. Dan,Alba Grifoni,Kathryn M. Hastie,Daniela Weiskopf,Simon Bélanger,Robert K. Abbott,Christina K. Kim,Jinyong Choi,Yu Kato,Eleanor G. Crotty,Cheryl Kim,Stephen A. Rawlings,Jose Mateus,Longping V. Tse,April Frazier,Ralph S. Baric,Bjoern Peters,Jason A. Greenbaum,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +28 more
TL;DR: A combined examination of all three branches of adaptive immunity at the level of SARS-CoV-2-specific CD4+ and CD8+ T cell and neutralizing antibody responses in acute and convalescent subjects suggested roles for both CD4 plus T cells in protective immunity in COVID-19.
Journal ArticleDOI
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi Xiangyang,Renhong Yan,Jun Zhang,Zhang Guanying,Yuanyuan Zhang,Hao Meng,Zhe Zhang,Pengfei Fan,Dong Yunzhu,Yilong Yang,Chen Zhengshan,Yingying Guo,Jinlong Zhang,Yaning Li,Xiaohong Song,Chen Yi,Lu Xia,Ling Fu,Lihua Hou,Junjie Xu,Changming Yu,Jianmin Li,Qiang Zhou,Wei Chen +23 more
TL;DR: The epitope of 4A8 is defined as the N-terminal domain (NTD) of the S protein by determining with cryo–eletron microscopy its structure in complex with the Sprotein, which points to the NTD as a promising target for therapeutic mAbs against COVID-19.
Related Papers (5)
Clinical value of anti-SARS-COV-2 serum IgA titration in patients with COVID-19.
Giuseppe Lippi,Camilla Mattiuzzi +1 more